Science, patient benefits, and productivity

Severin Schwan, CEO Roche Group

UBS Global Healthcare Conference NY, 2019

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words

such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by

discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ

materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors;

2 legislative and regulatory developments and economic conditions;

3 delay or inability in obtaining regulatory approvals or bringing products to market;

4 fluctuations in currency exchange rates and general financial market conditions;

5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;

6 increased government pricing pressures;

7 interruptions in production;

8 loss of or inability to obtain adequate protection for intellectual property rights;

9 litigation;

10 loss of key executives or other employees; and

11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or

earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per

share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website – www.roche.com

All mentioned trademarks are legally protected2

Performance update

Growing new assets

Productivity

Outlook

3

New products with strong momentum

4All absolute values are presented in CHFm reported; 1 Erivedge, Perjeta, Kadcyla, Gazyva, Esbriet, Cotellic, Alecensa, Tecentriq, Ocrevus, Hemlibra, and Xofluza; 2 MabThera & Herceptin in Europe & JP

13,583

14,826

+1,204+442

-12-391

Pharma biosimilarsexposed2

Pharma new

products1Q1 2018 Q1 2019Diagnostics

division

Pharmaother

products

CHFmCHFm % of Pharma sales

5

36.4% 35.7% 36.1%

Core operating profit

% of sales

14.1

17.8

18.7

2016 2017 2018

27.9%

33.4% 33.0%

Operating free cash flowCore EPS

14.5315.34

18.14

2016 2017 2018

18.4 19.0

20.5

2016 2017 2018

CHFbn +9% at CER +5% at CER+19%1 at CERCHF CHFbn

CER=Constant Exchange Rates; 1+8% at CER excl. US tax reform

2018: Strong Core results, significant operating free cash flow

Performance update

Growing new assets

Productivity

Outlook

6

Roche significantly advancing patient care

BTD’s and BDD’s reflecting the quality of our research

7* Real-Time Oncology Reviews (RTOR) pilot and BTD

Replace and extend the business: Excellent progress

Through continuously improving standard of care

Replace/extend existing businesses Entering new

franchises

8

MabThera/Rituxan

Gazyva,

Venclexta,

polatuzumab vedotin,

mosunetuzumab,

CD20 x CD3

Herceptin

Perjeta,

Kadcyla,

Herceptin + Perjeta SC

Avastin

Tecentriq,

Alecensa,

entrectinib

Lucentisfaricimab

Port delivery system (PDS)

Tamiflu Xofluza

Achievements 2018

MS:

Ocrevus

Hemophilia A:

Hemlibra

CNS:

SMA, Autism,

Huntington’s,

Alzheimer’s, NMOSD

SMA=spinal muscular atrophy; NMOSD=neuromyelitis optica spectrum disorder; RMS=relapsing MS; PPMS=primary progressive MS; R/R CLL=relapsed/refractory chronic lymphocytic leukemia;

AML=acute myeloid leukemia; BC=breast cancer; NSCLC=non-small cell lung cancer; SCLC=small cell lung cancer; TNBC=triple-negative BC; nAMD=neovascular age-related macular degeneration;

DME=diabetic macular edema, PDS= Port Delivery System

Strong launches:

Ocrevus, Perjeta, Hemlibra, Tecentriq, Alecensa

Pivotal readouts:

Gazyva+Ven 1L CLL

Kadcyla: HER2+ eBC

Tecentriq: 1L non-sq NSCLC, 1L SCLC & TNBC,

Entrectinib : ROS1+ NSCLC & NTRK+ tumors

Xofluza: US approval in Influenza A and B

satralizumab: NMOSD

Venclexta: R/R CLL & 1L AML

Proof of Concept:

faricimab: Ophtalmology- nAMD and DME

PDS: Ophtalmology - nAMD

risdiplam: SMA- Type 1/2/3

balovaptan: Autism in adults

What we have achievedFurther growth momentum /

new market entries

Tecentriq

Strong US launch in 1L SCLC; 2L NSCLC share gains in EU

9

YoY CER growthCHFm

CER=Constant Exchange Rates; NSCLC=non-small cell lung cancer; SCLC=small cell lung cancer; TNBC=triple negative breast cancer; HCC=hepatocellular carcinoma

(+) 1L HCC: Ph III readout in 2019

(+) Adj bladder cancer: Ph III readout in 2019 /20

(+) 1L Melanoma: Ph III readout in 2019

Main drivers: (+) 1L NSCLC (US/EU)

(+) 1L SCLC & 1L TNBC (US)

Replace and extend the business: Excellent progress

Through continuously improving standard of care

Replace/extend existing businesses Entering new

franchises

10

MabThera/Rituxan

Gazyva,

Venclexta,

polatuzumab vedotin,

mosunetuzumab,

CD20 x CD3

Herceptin

Perjeta,

Kadcyla,

Herceptin + Perjeta SC

Avastin

Tecentriq,

Alecensa,

entrectinib

Lucentisfaricimab

Port delivery system (PDS)

Tamiflu Xofluza

Achievements 2018

MS:

Ocrevus

Hemophilia A:

Hemlibra

CNS:

SMA, Autism,

Huntington’s,

Alzheimer’s, NMOSD

SMA=spinal muscular atrophy; NMOSD=neuromyelitis optica spectrum disorder; RMS=relapsing MS; PPMS=primary progressive MS; R/R CLL=relapsed/refractory chronic lymphocytic leukemia;

AML=acute myeloid leukemia; BC=breast cancer; NSCLC=non-small cell lung cancer; SCLC=small cell lung cancer; TNBC=triple-negative BC; nAMD=neovascular age-related macular degeneration;

DME=diabetic macular edema, PDS= Port Delivery System

Strong launches:

Ocrevus, Perjeta, Hemlibra, Tecentriq, Alecensa

Pivotal readouts:

Gazyva+Ven 1L CLL

Kadcyla: HER2+ eBC

Tecentriq: 1L non-sq NSCLC, 1L SCLC & TNBC,

Entrectinib : ROS1+ NSCLC & NTRK+ tumors

Xofluza: US approval in Influenza A and B

satralizumab: NMOSD

Venclexta: R/R CLL & 1L AML

Proof of Concept:

faricimab: Ophtalmology- nAMD and DME

PDS: Ophtalmology - nAMD

risdiplam: SMA- Type 1/2/3

balovaptan: Autism in adults

Neuroscience franchise

Ocrevus growth driven by new/ switch patients

11CER=Constant Exchange Rates

What we have achieved

YoY CER growthCHFm

Main drivers: (+) Strong launch in US/ EU

Increasing US market share

7% 8% 8%

21% 18% 14%

26%21%

16%

2%

3%

5%

11%

11%

10%

2%

3%

3%

19%

18%

17%

11%

10%

9%

8%16%

0%

20%

40%

60%

80%

100%

Total patient share- R3M (Jan 2017 to Jan 2019)

AUBAGIO ABREPs COPAXONE

GENERIC COPAXONE GILENYA LEMTRADA

RITUXAN TECFIDERA TYSABRI

OCREVUS

Jan 17 Jan 18 Jan 19

12Data at AAN 2019. *Defined as ≥16 hours per day continuously for ≥2 weeks. †Supports weight. Cohort 1: Low dose cohort. Cohort 2: Dose adjusted per protocol. Data cut-off: 27 February 2019. BSID-III, Bayley Scales of Infant Development, Third Edition; CHOP-INTEND, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders; HINE-2, Hammersmith Infant Neurological Examination, Section 2; SMA, spinal muscular atrophy.

A positive benefit-risk ratio for patients with Type 1 SMA

A compelling divergence from natural history

Risdiplam in SMA Typ 1 (FIREFISH-1) – strong 1 year results

Hemophilia A franchise

Transforming the market

13

Needs-based segmentation1

Total hemophila A market growing to USD 13bn by 20242

75-80%

target

population

5%

45%

15%

10%

20%

PWHA=People with Hemophilia A; Source: Treated patients MORSE 2017 (prevalence), UKHCDO Annual Report 2016 and internal assumptions (treatment rate); 1 Target population based on the US label; 2 Source: Evaluate Pharma

Inhibitors Non-inhibitor adults on treatment with bleeds

Non-inhibitor pediatric Non-inhibitor adults on treatment without bleeds

Non-inhibitor mild patients

Performance update

Growing new assets

Productivity

Outlook

14

Continuing to evolve our operating model

Build an effective organization for the future

• Simplify current set up for

Corporate, Pharma and Dia

• Centers in Kuala Lumpur,

Costa Rica, and Budapest

• Smaller, fit-for-purpose teams

with power to decide & act

• Resource shift to support key

launches

• Faster filing (strive for best in

class)

• Innovative trial designs

15

Corporate:

Shared Service Centers

Technical operations

• Reduction in COGS

• Cope with demand in China

• Lean management production

program

+11%

+3%

Volume Core COGS and

Period Costs

Sales organization

US

Europe

LATAM

APAC

EEMEA

US

International

Development

Performance update

Growing new assets

Productivity

Outlook

16

New products close to annualized sales of CHF 13bn*

Additional 4 NMEs approaching launch

17* Venclexta sales are booked by partner AbbVie and therefore not included.

CHFm % of Pharma sales

18

Q1 2019: Record number of NMEs at pivotal stage

entrectinib

polatuzumab vedotin

ipatasertib

Hemlibra (EU)

idasanutlin

Perjeta+Herceptin FDC SC

PDS with ranibizumab

faricimab

HTT-ASO

risdiplam

balovaptan

anti-myostatin adnectin

satralizumab

gantenerumab

Xofluza (EU)

etrolizumab

FY 2016 FY 2018

Hemlibra

idasanutlin

taselisib

Alecensa

Tecentriq

lampalizumab

crenezumab

satralizumab

gantenerumab

Ocrevus

etrolizumab

NM

Es

lin

e

exte

nsio

ns

5

1

33

3

1

37

3

Oncology

Neuroscience

Ophthalmology

Immunology

Infectious Disease

polatuzumab vedotin

ipatasertib

Hemlibra

idasanutlin

taselisib

faricimab

risdiplam

balovaptan

anti-myostatin adnectin

crenezumab

satralizumab

gantenerumab

Ocrevus

Xofluza

etrolizumab

FY 2017

4

1

31

NME=new molecular entities; FDC=Fixed dose combination; SC=Subcutaneous; PDS=Port delivery system; For details on the indications and line extensions please consult the pipeline appendix

entrectinib

polatuzumab vedotin

ipatasertib

idasanutlin

Perjeta+Herceptin FDC SC

PDS with ranibizumab

faricimab

HTT-ASO

risdiplam

balovaptan

anti-myostatin adnectin

satralizumab

gantenerumab

Xofluza (EU)

etrolizumab

Q1 2019

2

1

34

4

2019 outlook raised

Sales growth to “mid-single digit” from “low- to mid-single digit”

19

Group sales growth1 • Mid-single digit (from low- to mid-single digit)

Core EPS growth1 • Broadly in line with sales

Dividend outlook • Further increase dividend in Swiss francs

1 At Constant Exchange Rates (CER)

Doing now what patients need next